Zydus Lifesciences Ltd - Stock Valuation and Financial Performance

BSE: 532321 | NSE: ZYDUSLIFE | Pharmaceuticals & Drugs | Large Cap

Zydus Lifesciences Share Price

1,171.65 7.35 0.63%
as on 12-Jul'24 16:01

DeciZen - make an informed investing decision on Zydus Lifesciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Zydus Lifesciences stock performance -

mw4me loader
P/E Ratio (CD):
30.63
Market Cap:
1,18,217.4 Cr.
52-wk low:
564.1
52-wk high:
1,203.2

Is Zydus Lifesciences Ltd an attractive stock to invest in?

1. Is Zydus Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Zydus Lifesciences Ltd is a good quality company.

2. Is Zydus Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Zydus Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Zydus Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Zydus Lifesciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Zydus Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zydus Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 14.2%18%25.7%14.8%14%11.8%7.4%12.4%10%10.3%-
Value Creation
Index
0.30.61.30.30.20.1-0.30.1-0.1-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 7,2248,6519,4279,37711,90513,16614,25314,40415,11017,23719,547
Sales YoY Gr.-19.8%9%-0.5%27%10.6%8.3%1.1%4.9%14.1%-
Adj EPS 7.711.318.914.417.418.211.922.520.121.538.4
YoY Gr.-46.8%67.9%-23.6%20.6%4.3%-34.5%89.5%-11%7.1%-
BVPS (₹) 33.641.555.76885.4101.4101.3126.9166173.1197.1
Adj Net
Profit
7851,1531,9361,4781,7821,8591,2172,3072,0542,1743,860
Cash Flow from Ops. 9039941,8941,3129191,2822,9323,2942,1052,689-
Debt/CF from Ops. 32.71.345.96.22.71.420.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.2%7.7%6.5%14.1%
Adj EPS 12.1%4.3%21.8%7.1%
BVPS20%15.2%19.5%4.3%
Share Price 18% 37.8% 22% 98.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
24.63038.923.422.719.411.719.713.712.620.7
Op. Profit
Mgn %
16.620.324.720.323.922.719.623.62120.727.9
Net Profit
Mgn %
11.313.720.415.714.714.18.51614.212.819.8
Debt to
Equity
0.80.60.40.80.60.80.80.40.30.10
Working Cap
Days
155153158178185213210103107102100
Cash Conv.
Cycle
666153638010110310182055

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 20.70%

Net Profit is growing at healthy rate in last 3 years 21.79%

Sales growth is good in last 4 quarters at 12.96%

Sales growth has been subdued in last 3 years 6.54%

Latest Financials - Zydus Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 34.2 38.4
TTM Sales (₹ Cr.) 10,819 19,547
BVPS (₹.) 156.2 197.1
Reserves (₹ Cr.) 15,616 19,729
P/BV 7.52 5.96
PE 34.35 30.63
From the Market
52 Week Low / High (₹) 564.05 / 1203.20
All Time Low / High (₹) 5.53 / 1203.20
Market Cap (₹ Cr.) 1,18,217
Equity (₹ Cr.) 100.6
Face Value (₹) 1
Industry PE 43.9

Management X-Ray of Zydus Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Zydus Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales8,6519,4279,37711,90513,16614,25314,40415,11017,23719,547
Operating Expenses 6,8977,0977,4729,05810,18711,47311,01811,93513,66614,248
Manufacturing Costs1,2821,5531,1301,8922,1552,4832,5032,5722,9833,124
Material Costs2,8142,6733,0653,6574,1414,2434,0944,7575,3365,260
Employee Cost 1,0971,1191,4851,6451,9032,1702,0702,1782,4562,789
Other Costs 1,7051,7521,7921,8641,9882,5772,3522,4292,8903,075
Operating Profit 1,7542,3301,9042,8472,9782,7803,3853,1753,5725,299
Operating Profit Margin (%) 20.3%24.7%20.3%23.9%22.6%19.5%23.5%21.0%20.7%27.1%
Other Income 5711714713320911775391475369
Interest 68536311119634218612713081
Depreciation 287292373539599697670713723764
Exceptional Items -10-300-10-364-205113-604-14
Profit Before Tax 1,4462,0991,6152,3312,3821,4952,3992,8382,5904,809
Tax 259177129564530320194512588978
Profit After Tax 1,1861,9211,4861,7661,8521,1762,2062,3262,0023,831
PAT Margin (%) 13.7%20.4%15.8%14.8%14.1%8.2%15.3%15.4%11.6%19.6%
Adjusted EPS (₹)11.218.914.517.318.111.520.843.819.438.4
Dividend Payout Ratio (%)21%17%22%20%19%30%17%6%31%8%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 4,2525,6996,9608,74510,38610,37612,99217,00017,51619,830
Share Capital 102102102102102102102102101101
Reserves 4,1495,5976,8588,64210,28410,27312,89016,89717,41519,729
Minority Interest169136156191129313351937205421732272
Debt2,3342,1074,9455,1137,1477,0413,6803,6761,081769
Long Term Debt1,1508962,4682,5553,9503,21561036200
Short Term Debt1,1841,2112,4772,5583,1973,8273,0713,3141,081769
Trade Payables1,0911,3081,5481,8881,9232,0442,2062,1382,1252,127
Others Liabilities 1,2027827161,2041,7642,0381,9941,8321,6002,640
Total Liabilities 9,04710,03214,32517,14122,51322,83422,81026,70024,49427,637

Fixed Assets

Gross Block5,1395,7678,1039,34915,70216,78217,34517,65118,34419,920
Accumulated Depreciation1,7862,0172,3462,8673,5394,5515,2125,4626,8237,551
Net Fixed Assets3,3523,7515,7576,48312,16412,23112,13312,18911,52112,369
CWIP 7989511,5431,5278377427837261,2012,423
Investments 1544164357466747658303,2881,5471,221
Inventories1,5361,3371,8042,3852,6882,7893,2363,7193,4133,442
Trade Receivables1,5881,7472,2783,2063,9513,6633,1273,3404,4175,220
Cash Equivalents 6706391,5441,3155499658881,1075731,105
Others Assets9491,1929651,4791,6511,6801,8122,3311,8231,857
Total Assets 9,04710,03214,32517,14122,51322,83422,81026,70024,49427,637

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 9941,8941,3129191,2822,9323,2942,1052,6893,228
PBT 1,4462,0991,6122,3122,3821,4952,2855,2322,5834,838
Adjustment 3452503346245391,4741,163-2,117934547
Changes in Working Capital -377272-411-1384-972264191-336-236-871
Tax Paid -387-646-238-602-675-303-345-675-592-1,286
Cash Flow From Investing Activity -465-864-2,872-974-4,239-1,012-725-1,0001,535-1,475
Capex -496-957-2,935-1,035-1,046-889-847-1,055-992-883
Net Investments -1116512-4,74629-39-2,8632,298-419
Others 427858501,554-1521612,918229-173
Cash Flow From Financing Activity -351-9352,316521,885-1,528-2,548-868-4,400-1,810
Net Proceeds from Shares 000000987000
Net Proceeds from Borrowing -330-2371,4991011,808-786-2,568-674-841-83
Interest Paid -67-44-56-105-80-324-184-111-126-73
Dividend Paid -184-572-3270-358-715-2-372-267-621
Others 230-821,19956514296-781289-3,166-1,034
Net Cash Flow 17895756-3-1,07239122236-177-58
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)30.8538.6223.4722.519.3611.3218.8815.5111.620.52
ROCE (%)23.2128.616.5218.5515.8910.0214.3815.313.6424.9
Asset Turnover Ratio1.031.010.790.760.660.631.271.191.321.46
PAT to CFO Conversion(x)0.840.990.880.520.692.491.490.91.340.84
Working Capital Days
Receivable Days56637784999743404246
Inventory Days60556064707038433833
Payable Days130164170171168171189167146148

Zydus Lifesciences Ltd Stock News

Zydus Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Zydus Lifesciences on 12-Jul-2024 16:01 is ₹1,171.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Jul-2024 16:01 the market cap of Zydus Lifesciences stood at ₹1,18,217.4.
The latest P/E ratio of Zydus Lifesciences as of 12-Jul-2024 16:01 is 34.35.
The latest P/B ratio of Zydus Lifesciences as of 12-Jul-2024 16:01 is 7.52.
The 52-week high of Zydus Lifesciences is ₹1,203.2 and the 52-week low is ₹564.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zydus Lifesciences is ₹10,819 ( Cr.) .

About Zydus Lifesciences Ltd

Cadila Healthcare Limited, a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations. The company’s shares are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The company’s initiatives in the areas of research and development span across the pharmaceuticals value chain, including New Chemical Entities (NCE), biologics, vaccines, specialty and complex generic formulations and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The company has a pool of modern, cost efficient and regulatory compliant manufacturing facilities which ensures continuous supply of high quality products at the most competitive prices to its customers across the globe.

Business area of the company

The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.

Business verticals / products

  • Human Health Formulations
  • Consumer Wellness
  • Animal Healthcare

Awards

2008-09:

  • The Company received the 'Social and Corporate Governance Awards 2008' in the 'Best Social Responsibility Practice' category presented by the BSE, NASSCOM Foundation and Times Foundation jointly.

2009-10:

  • Received the 'IMAI OE Award for the Pioneering and Paradigm Shifting Applications of OE in Tablet Manufacturing' by the KAIZEN Institute.
  • Received the 'Best-In-Class Manufacturing Award (Pharma Sector)' by Stars of the Industry Awards.

2010-11:

  • Declared the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010.

2011-12:

  • Zydus Research Centre, Ahmedabad has achieved the full AAALAC accreditation for the fourth year in a row. It has also received accreditation from College of American Pathologists (CAP) upon completion of the inspection process. This accreditation was received in the first inspection itself.

2012-13:

  • The Gujarat Ecology Commission selected the Company for good ‘Environment-friendly Practices in Gujarat’. Zydus Research Centre won the Safety Award for the third consecutive year from Gujarat Safety Council.

2013-14:

  • Moraiya formulations facility was awarded the 'Gold Award - Pharma Sector, Mega Large Business' by The Economic Times and Frost & Sullivan for achieving operational excellence.

2014-15:

  • The Moraiya formulations facility was awarded the 'Green Manufacturing Award - Gold Category' by International Research Institute for Manufacturing.
  • The Baddi formulations facility was awarded 'Gold Certificate Merit' in IMEA - India Manufacturing Excellence Awards 2014 by The Economic Times in partnership with Frost & Sullivan.

2015-16:

  • It was awarded the Overall India Pharma Excellence Award and the India Pharma Innovation of the Year Award from the Department of Pharmaceuticals, Government of India.

2016-17:

  • Topical formulations facility received the ‘Silver Certificate of Merit’ from Frost & Sullivan at India Manufacturing Excellence Awards 2016.

2017-18:

  • The manufacturing sites at Moraiya, Baddi and Sikkim received the Silver medal at the National Award for Manufacturing Competitiveness (NAMC) by IRIM global.
  • API manufacturing facility at Ankleshwar Ank Unit I bagged a Silver at the Greentech Safety Award 2017 in recognition of its safety systems from the Greentech Foundation, Environment.

2018-19:

  • Moraiya formulations manufacturing facility received the Gold Award in the category of Pharma Sector, Large Business at the India Manufacturing Excellence Awards, 2018.

2019-20:

  • Cadila Healthcare Limited received CSIR Diamond Jubilee Technology Award for Discovery & Development of Saroglitazar in June 2019.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.